Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Psychopharmacology Bulletin|January 14, 2026
Differences in the Prevalence of Use and Dosage of Psychotropic Drugs by Smoking Status in Inpatient and Outpatient: An Observational, Analytical, Cross-Sectional StudyPedro Damian Gargoloff, Martín A Urtasun, Raul Riveros, et al.Salud Colectiva|April 6, 2021
[Reduction of social coverage for symptomatic slow-acting drugs for osteoarthritis: a disinvestment initiative in Argentina, 2015-2017]Martín A Urtasun, María Noble, Martín Cañás, et al.Revista Colombiana De Obstetricia Y Ginecologia|December 16, 2025
Use of nervous system medications with fetal risk before and during pregnancy in an Argentine social security systemCecilia Anahi Alvarez Rotondo, Gustavo H Marín, Lupe Marín, et al.Revista Panamericana De Salud Publica = Pan American Journal of Public Health|April 16, 2021
Regulatory reliance to approve new medicinal products in Latin American and Caribbean countriesCarlos E Durán, Martín Cañás, Martín A Urtasun, et al.Medicina|October 5, 2018
[Cardiovascular risk of non-steroidal anti-inflammatory drugs]Guillermo R Prozzi, Martín Cañás, Martín A Urtasun, et al.Medicina|May 31, 2022
[Use of benzodiazepines and related drugs in social security for older adults in Argentina]Martín A Urtasun, María Noble, Martín Cañás, et al.Salud Colectiva|June 9, 2021
Data transparency for building a stronger healthcare system: A case study from Argentinean administrative drug utilization data sourcesMartín Cañás, Gustavo H Marín, Martín A Urtasun, et al.Therapeutic Innovation & Regulatory Science|March 4, 2024
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and ItalyFernanda Lacerda da Silva Machado, Martín Cañás, Martín A Urtasun, et al.Regulatory Toxicology and Pharmacology : RTP|September 2, 2023
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparisonFernanda Lacerda da Silva Machado, Martín Cañás, Svetlana V Doubova, et al.Pageof 2